Chronic kidney disease (CKD) stage 3 represents a moderate decrease in renal function, clinically defined by an estimated glomerular filtration rate (eGFR) between 30 and 59 mL/min/1.73m². This stage is a pivotal point in the progression of kidney disease where physiological complications such as hypertension, anemia, and early-stage mineral and bone disorders often become clinically manifest. Code N18.30 is the appropriate ICD-10-CM designation when the documentation confirms stage 3 CKD but does not specify whether the patient is in stage 3a (mild-to-moderate, eGFR 45-59) or stage 3b (moderate-to-severe, eGFR 30-44). Management focus at this stage involves aggressive risk factor modification to prevent progression to stage 4 or end-stage renal disease (ESRD), adjustment of medication dosages, and monitoring for metabolic complications.
Explicitly link the chronic kidney disease to its underlying etiology such as diabetes or hypertension.
Example: Assessment: Chronic kidney disease, stage 3 unspecified (N18.30). The patient's decline in GFR to 48 mL/min/1.73m2 is attributed to long-standing Type 2 Diabetes Mellitus. Plan: Continue Losartan 50mg daily for nephroprotection.
Billing Focus: Diagnosis linkage using 'due to' or 'associated with' to support manifestation coding.
Document the duration of kidney dysfunction to confirm chronicity of at least three months.
Example: Subjective: Patient here for follow-up of renal function. Lab work from six months ago showed a GFR of 52, and today's GFR is 50. This confirms the diagnosis of Chronic Kidney Disease, Stage 3.
Billing Focus: Ensures the condition meets the ICD-10 definition of chronic rather than acute.
Use specific GFR values to justify the stage, even if the sub-stage (3a or 3b) is not documented.
Example: Objective: Labs today show Creatinine 1.8, GFR 44 mL/min/1.73m2. Assessment: CKD stage 3 unspecified. Management: Review diet and avoid NSAIDs.
Billing Focus: Clinical validity through laboratory evidence supports the level of specificity.
Document any associated complications like anemia or mineral bone disease.
Example: Assessment: Chronic kidney disease, stage 3 unspecified with secondary anemia. Hemoglobin is 10.2 g/dL. Plan: Start oral iron supplementation and monitor CBC.
Billing Focus: Identifies secondary conditions that may require additional CPT codes and higher MDM levels.
When GFR falls between 30 and 59, use Stage 3. If unspecified between 3a and 3b, N18.30 is appropriate but sub-staging is preferred.
Example: Assessment: CKD stage 3 (N18.30). GFR is 38. While this technically falls into stage 3b, the provider documentation only notes stage 3.
Billing Focus: Coding specificity must match the provider's exact terminology.
Standard follow-up for a stable patient with CKD stage 3 where the provider manages a low-complexity condition.
Used when managing CKD stage 3 alongside comorbidities like DM or HTN, requiring moderate complexity of data review.
Appropriate for CKD stage 3 patients experiencing acute complications or severe exacerbations of comorbid conditions.
Essential diagnostic test to calculate GFR and determine the CKD stage.
Used to monitor for proteinuria, a key indicator of renal disease progression in stage 3.
Includes creatinine and BUN, which are vital for tracking the status of CKD.
Helpful in assessing the nutritional status and potential protein loss in CKD patients.
Used to rule out obstructive uropathy or assess kidney size in patients with stage 3 CKD.
Initial consultation for a new patient diagnosed with stage 3 CKD presenting with low complexity.
Initial nephrology consultation for a patient with stage 3 CKD and multiple comorbidities.